Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBITDA Margin (2016 - 2025)

Regenxbio (RGNX) has 12 years of EBITDA Margin data on record, last reported at 221.46% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2057.0% year-over-year to 221.46%; the TTM value through Dec 2025 reached 113.72%, up 15439.0%, while the annual FY2025 figure was 113.72%, 15439.0% up from the prior year.
  • EBITDA Margin reached 221.46% in Q4 2025 per RGNX's latest filing, down from 207.99% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 73.43% in Q4 2021 and bottomed at 397.71% in Q1 2024.
  • Average EBITDA Margin over 5 years is 237.81%, with a median of 240.69% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: crashed -25553bps in 2022, then surged 40452bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 73.43% in 2021, then tumbled by -348bps to 182.1% in 2022, then crashed by -48bps to 269.68% in 2023, then grew by 10bps to 242.03% in 2024, then rose by 9bps to 221.46% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 221.46% in Q4 2025, 207.99% in Q3 2025, and 331.75% in Q2 2025.